Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
The company also posted sales of its popular weight-loss and diabetes drugs below analysts' expectations, which it attributed ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot ... the diabetes shot that’s often taken ...
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Analysts expect the Danish company to start catching up. Less than a year after Eli Lilly began selling Zepbound, sales for ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...